|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
Outcomes with Immune Checkpoint Inhibitors in Patients with MTAP Alterations in Advanced Urothelial Carcinoma
|
Rafee Talukder, MD
Rafee Talukder joins Petros Grivas to discuss his research into the effects of MTAP loss on survival rates among advanced urothelial cancer patients undergoing immunotherapy.
|
|
|
|
|
|
|
|
|
New Therapeutic Targets and Investigational Drugs in the Pipeline for Advanced Bladder Cancer
|
Joaquim Bellmunt, MD, Ph.D.
Alicia Morgans speaks with Joaquim Bellmunt about advances in urothelial carcinoma. Dr. Bellmunt outlines the progress and challenges in targeted therapies, such as PARP inhibitors, antibody drug conjugates, and immunotherapy checkpoint inhibitors.
|
|
|
|
|
|
|
|
|
Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma
|
Jonathan Rosenberg, MD
Jonathan Rosenberg joins Alicia Morgans to discuss the long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial.
|
|
|
|
|
|
|
|
|
Exploring Genetic Biomarkers of Response to Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of The UNITE Dataset
|
Vadim Koshkin, MD, and Tanya Jindal, BS, BA
Tanya Jindal and Vadim Koshkin join Petros Grivas to discuss their work to help identify potential biomarkers of response to enfortumab vedotin (EV) in patients with advanced urothelial carcinoma using a patient cohort in the UNITE dataset.
|
|
|
|
|
|
|
|
Phase 3 THOR Study: Results of Erdafitinib Versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations
|
Yohann Loriot, MD, Ph.D. |
Yohann Loriot discusses the results of the phase 3 THOR study assessing erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations. These results support the role of erdafitinib as the standard of care for the treatment of patients with FGFRalt metastatic urothelial cancer after PD-(L)1 therapy.
|
|
|
|
|
Discussant: THOR – Results of Erdafitinib versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations
|
Daniel Petrylak, MD
|
Daniel Petrylak provides a discussant presentation of the THOR study of erdafitinib vs chemotherapy for patients with advanced or metastatic urothelial carcinoma. The THOR study demonstrated superior overall survival, PFS, and objective response rates of erdafitinib compared to single-agent chemotherapy in patients with FGFR3/2 alterations. Future studies are needed to develop rational sequencing of erdafitinib, enfortumab vedotin, and sacituzumab govitecan.
|
|
|
|
|
|
|
|
|
Long-Term Safety of Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial
|
Joaquim Bellmunt, MD, Ph.D. |
Joaquim Bellmunt discusses the long-term safety outcomes of using avelumab as first-line maintenance therapy for advanced urothelial carcinoma, based on the JAVELIN Bladder 100 trial. He presents findings on the treatment's safety profile, potential adverse effects, and its overall impact on patients with advanced bladder cancer, providing insights into the durability and safety of this therapeutic approach. |
|
|
|
|
Treatment Rechallenge with Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma - Beyond the Abstract
|
Vadim Koshkin, MD, Rafee Talukder, MD, Ali Khaki, MD, and Petros Grivas, MD, Ph.D.
|
Vadim Koshkin, Rafee Talukder, Ali Khaki, and Petros Grivas explore the concept of treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma. They delve into the rationale, feasibility, and potential benefits of reintroducing immune checkpoint inhibitors as a treatment strategy in cases where patients have previously received such therapies, shedding light on the evolving landscape of treatment options for advanced bladder cancer.
|
|
|
|
|
State-of-the-Art Lecture: Psycho-Oncological Counselling of Locally Advanced Bladder Cancer
|
Christian Schulz-Quach, MD, MSc, MA, FHEA, MRCPsych
|
Christian Schulz-Quach provides a state-of-the-art lecture on psycho-oncological counseling in the context of bladder cancer. He gives insights into the importance of addressing the psychological and emotional aspects of bladder cancer diagnosis and treatment, highlighting the role of psycho-oncological counseling in improving patients' well-being and overall quality of life during their cancer journey.
|
|
|
|
|
Safety and Efficacy of Rogaratinib Versus Chemotherapy in Advanced Bladder Cancer - Expert Commentary
|
Bishoy Faltas, MD
|
Bishoy Faltas provides an expert commentary review discussing the safety and efficacy of rogaratinib compared to chemotherapy in the treatment of advanced bladder cancer. The commentary provides insight into the findings of a study discussing the potential benefits and limitations of rogaratinib as a therapeutic option for patients with advanced bladder cancer and its implications for the field of urologic oncology.
|
|
|
|
|
|
|
|
|
|